Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Orally Administered BMS-986485 in Healthy Adult Participants (Part A), and a Conditional Open-label Study to Evaluate the Relative Bioavailability of Alternate Formulations of BMS-986485 in Healthy Adult Participants (Part B)
NCT07887763 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Orally Administered BMS-986485 in Healthy Adult Participants (Part A), and a Conditional Open-label Study to Evaluate the Relative Bioavailability of Alternate Formulations of BMS-986485 in Healthy Adult Participants (Part B)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 3, 2026
- Completion date
- June 8, 2027
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers
Arms
As registered; 2 arms.
-
Part A: SAD
-
Part B: Conditional rBA
Primary endpoints
Registered primary outcome measures; 18 primary.
-
Number of participants with Treatment Emergent Adverse Events (TEAEs)
-
Number of participants with Serious Adverse Events (SAEs)
-
Number of participants with Vital Signs abnormalities
-
Number of participants with Physical Examination abnormalities
-
Number of Participants with 12-Lead Electrocardiogram (ECG) abnormalities
+13 more primary endpoints
Lead sponsor's other trials
Bristol-Myers Squibb, most recent start first.
+1,554 more trials See the organization page